LOGIN  |  REGISTER
Compass Therapeutics

TransMedics to Present at Upcoming March Investor Conferences

February 28, 2024 | Last Trade: US$142.69 0.35 -0.24

ANDOVER, Mass., Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 9:50 a.m. EST and to present virtually at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on Tuesday, March 12, 2024, at 12:40 p.m. EST.

Event: TD Cowen 44th Annual Health Care Conference
Date: Monday, March 4, 2024
Time: 9:50 a.m. EST

Event: Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Date: Tuesday, March 12, 2024
Time: 12:40 p.m. EST

A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
332-895-3222
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Terns Pharmaceuticals

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page